地拉罗司怎么使用呢？

It was approved by the FDA in November 2005 for use in patients 2 years and older with chronic iron overload caused by blood transfusions. In December 2012, Deferasirox was approved by the European Commission for the treatment of chronic iron overload in patients aged 10 years and older with non-transfusion-dependent thalassemia (NTDT) syndrome who require chelation therapy due to contraindications or insufficiency of deferoxamine mesylate therapy. On January 23, 2013, the FDA approved a new indication for deferasirox for the treatment of chronic iron overload in patients aged 10 years and older with non-transfusion-dependent thalassemia (NTDT).

The common starting dose is 20 mg/(kg·d). If there is a large amount of blood transfusion and the iron increase is >0.5 mg/(kg·d) or the iron load before treatment is high, the recommended dose is 30 mg/(kg·d). If the iron increase is <0.3 mg/kg, 10-15 mg/kg/d is enough to control the disease. Administer on an empty stomach 30 minutes before meals and should be completely dissolved in water or apple or orange juice. Lower doses of deferasirox [5-10 mg/(kg·d)] can only be used in young patients with mild iron overload and few blood transfusions, or in elderly patients who have not received satisfactory results from chelation therapy in the past; patients using deferasirox 20 and 30 mg/(kg·d) need to carefully monitor body iron stores, because body iron levels may continue to rise in 50% and 10% of patients. In addition, the frequency of blood transfusion can also affect the effect of deferasirox in controlling liver concentration. When the iron intake is greater than 0.5 mg/(kg·d), only 47% of patients who receive the same dose of deferasirox have a reduction in liver concentration.

Drug interactions: 1. Avoid combination with strong inducers of UDP-glucuronyltransferase (UGT) (such as rifampicin, phenytoin, sedatives and hypnotics, protease inhibitors), cholestyramine. 2. 不能与含铝的抗酸剂同时给药。 Not to be combined with other iron chelation treatments. 3. Be careful with repaglinide, drugs with potential ulcerogenic effects such as NSAIDs, cortisones, or oral bisphosphonates, drugs metabolized by CYP3A4 (such as cyclosporine, simvastatin, hormonal contraceptives). Withhold Enrig at least 5 days before performing Gallium-67 imaging.

特殊人群使用：妊娠期妇女禁用。 Breastfeeding women must consult a doctor before use. If they really need to use it, they should choose to suspend breastfeeding.